GlassScriptPhysician profile
Robert M Shively
NPI 1750334991
$201.09
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.34 | 2019 | |
| Glaxosmithkline, LLC. | $40.30 | 2019 | |
| Pfizer INC. | $39.66 | 2019 | |
| Novo Nordisk INC | $25.58 | 2019 | |
| Antares Pharma, INC. | $15.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.